ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 6002 participants.

Also called NCT04609111

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 6,002 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04609111
Other papers using this trial's data
  • An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial Circulation, 2024-02-20 DOI, PubMed 37994553 PubMed links an erratum for this paper. Erratum: PMID 38739699
  • Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral Anticoagulation Circulation. Cardiovascular interventions, 2025-11 DOI, PubMed 40988628
  • Aspirin vs Clopidogrel 1 Month After Acute Coronary Syndrome With High-Bleeding Risk or ST-Segment Elevation JACC. Cardiovascular interventions, 2025-09-08 DOI, PubMed 40471776
  • Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial European heart journal, 2024-12-16 DOI, PubMed 39215959
  • Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial European heart journal. Cardiovascular pharmacotherapy, 2025-03-13 DOI, PubMed 39863419, PMC11905749 In the PMC Open Access subset under CC BY-NC.
  • Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 Trial Circulation. Cardiovascular interventions, 2025-07 DOI, PubMed 40365675
  • Post-procedural Anticoagulation With Unfractionated Heparin in Acute Coronary Syndrome: Insight from the STOPDAPT-3 Trial The American journal of cardiology, 2024-09-01 DOI, PubMed 38972535

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04609111. Randomized; no masking; primary purpose treatment. Start 2021-01-29 (actual); primary completion 2023-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study
Acronym
STOPDAPT-3
Condition
Acute Coronary Syndrome
Intervention (Drug)
No aspirin
Intervention (Drug)
1-month DAPT
Lead sponsor
Kyoto University, Graduate School of Medicine (class: other)

Record details

Record id
cardio:ct-nct04609111
Content hash
30ad20ffb27772f44bb75328a4fc0ed09b4f44073b5c028245f50f205464e599